Key result
HDL mimetic CER-001 targets progressive kidney function decline in familial LCAT deficiency.
Why the study?
No approved treatment is available for familial lecithin–cholesterol acyltransferase deficiency, a rare disease causing progressive organ damage.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
CER-001 for Inherited Lecithin–Cholesterol Acyltransferase Deficiency Background: No approved treatment is available for familial lecithin–cholesterol acyltransferase (LCAT) deficiency, a rare recessively inherited disease characterized by circulating free cholesterol-rich lipoprotein X (LpX) and very low levels of highdensity lipoprotein (HDL), leading to the progressive development of corneal ring opacities, anemia, splenomegaly, and glomerulopathy (1). In an animal model of familial LCAT deficiency, CER-001, an apolipoprotein A1 (apoA-1)–containing HDL mimetic, reduced LpX deposition, improved dyslipidemia, and prevented inflammation and renal damage (2). Objective: To determine whether CER-001 can improve the outcome of a patient with familial LCAT deficiency. Case Report: A 37-year-old woman was referred for nephrotic syndrome. Blood tests showed regenerative anemia; chronic kidney disease (estimated glomerular filtration rate [eGFR], 29 mL/min/1.73 m); and dyslipidemia, characterized by very low plasma levels of HDL cholesterol (0.32 mmol/L [12.4 mg/dL]) and apoA-1 (0.41 g/L) (Table) and by circulating LpX. Cardiovascular screening results were normal. She had splenomegaly and white corneal ring opacities; visual acuity was normal but the patient experienced blurred vision, especially at night. Ophthalmologic examination showed hyperreflective corneal opacification. Kidney biopsy showed mesangial hypertrophy with glomerular lipids and massive mesangial C3 and C5b9 deposits and a thickened glomerular basement membrane. Electron microscopy showed numerous pseudomyelin lipid deposits within the mesangial and endothelial cells, leading to capillary obstruction and pseudomembranous aspects. Glomerular proteome analysis confirmed enrichment of complement pathway components C3, C4, C8, andC9. The patient was identified as compound heterozygous for 2 LCAT gene variations: missense variation p.(Ile202Thr) and splice-site variation c.154+5G>C. Because treatment with antihypertensive medications and atorvastatin did not stop further kidney function decline, treatment with CER-001 was started (Figure). CER-001 was provided by Abyonyx Pharma; this company had no access to the data during the treatment period and did not participate in the writing of the manuscript or the LETTERS
No takes yet. Share an insight, caveat, or question.
Faguer et al. (2021) conducted a case report in familial lecithin-cholesterol acyltransferase (LCAT) deficiency (n=1). CER-001 was evaluated on kidney function decline. Treatment with the high-density lipoprotein mimetic CER-001 was initiated in a 37-year-old woman with familial LCAT deficiency and progressive kidney function decline.
Synapse has enriched 10 related papers. Consider them for comparative context: